Nektar TherapeuticsNKTR

Nektar Therapeutics’ latest quarterly filing is a masterclass in how to turn partnership headlines into cash-flow footnotes. Revenue for the three months to 31 March 2026 was $10.9 million, down from the previous period, while the company posted a net loss of $44.9 million and an operating cash burn of $44.3 million. Diluted earnings per share came in at -$1.82 on 24.7 million diluted shares, and the balance sheet’s cash pile is now $149.6 million against liabilities of $187.1 million, leaving stockholders’ equity at $576.2 million. In short, Nektar is running a deficit that would make a venture capitalist reach for the smelling salts. (source: Nektar Therapeutics 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/906709/000119312526212596/nktr-20260331.htm)

What the company does today is largely a relic of its past: Nektar still earns low-single-digit royalties and up to $40 million in regulatory milestones from its collaboration with UCB on dapirolizumab pegol, but the pipeline that once promised blockbuster returns is now a shadow of its former self. The firm’s clinical-trials page still touts active studies in immune-mediated diseases, yet the accompanying 10-Q reveals that research and development spend was $35.7 million in the quarter-good money chasing diminishing prospects. Nektar’s website may still talk of “partnering for innovation,” but the filings show the company has outsourced its own equity distribution, signing an agency agreement that pays Guggenheim and H.C. Wainwright a 3.0% commission on any stock they manage to sell. (source: Nektar Therapeutics 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/906709/000119312526212596/nktr-20260331.htm; Equity Distribution Agreement, https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808dex11.htm; Nektar clinical trials page, https://www.nektar.com/clinical-trials/)

The numbers tell the real story. At 31 March 2026, Nektar’s balance sheet showed $763.3 million in assets, but $187.1 million in liabilities left stockholders’ equity at $576.2 million. Cash and equivalents were $149.6 million, and the quarter saw a net cash outflow from operations of $44.3 million. Inventory remains at zero, and capital expenditure for the period was a rounding error at $18,000. The company’s diluted share count is 24.7 million, and while the board’s SEC filings show no shares left under the April 2025 ATM facility, the firm still managed to pay agents 3.0% commissions on any equity sold-hardly the stuff of high-margin biotech. (source: Nektar Therapeutics 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/906709/000119312526212596/nktr-20260331.htm; Equity Distribution Agreement, https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808dex11.htm)

The route to a deeper file is straightforward: a partner milestone payment that actually lands, clinical data that revives a programme, or a credible path to monetise one of the “11 approved medicines” beyond the low-single-digit royalties already promised. Until then, Nektar’s quarterly story is less a tale of innovation and more a story of how to stretch a balance sheet thinner than a VC’s patience. (source: Nektar Therapeutics 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/906709/000119312526212596/nktr-20260331.htm; Nektar partnering page, https://www.nektar.com/partnering-for-innovation/)

For chart context, the company trades on the Nasdaq under the ticker NKTR. The trading venue is the Nasdaq Stock Market, and the primary regulator is the U.S. Securities and Exchange Commission. The filings that matter are documented on SEC EDGAR under CIK 0000906709, where the most recent 10-Q and ownership XML updates sit. (source: SEC EDGAR CIK 0000906709, https://www.sec.gov/edgar/browse/?CIK=906709; SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000906709.json)